Intelligence / Healthtech / New Clinical Trials / Swedish Orphan Biovitrum
Swedish Orphan Biovitrum
27 Oct 2026: Trial registered · A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 27 Oct 2026
- Title
- A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
- Conditions
- C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- Brazil, Canada, Finland, France, Germany, Italy, Saudi Arabia, Spain, Switzerland, United Kingdom
- Country
- Brazil
- Reference
- NCT07898774
- Location
- Brazil, Canada, Finland
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Swedish Orphan Biovitrum
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Swedish Orphan Biovitrum in our registers.
More from Brazil
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.